Plain-English translation of NCT05204888 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether a home breathing device called myAirvo 3 can help people with moderate to very severe COPD (a serious lung disease that makes breathing difficult). The device delivers warm, humidified air through a small nasal tube, and researchers want to know if using it at home can help patients avoid serious lung flare-ups and stay out of the hospital. Half of the participants will use the myAirvo 3 device at home, and the other half will receive usual care only.
Many people with severe COPD experience serious flare-ups that send them to the hospital. This treatment is designed to help keep the airways open and reduce the number and severity of these flare-ups, potentially helping patients breathe easier and stay healthier at home.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will either receive the myAirvo 3 device to use at home (at least 8 hours daily, preferably overnight) or receive usual COPD care without the device. Both groups will record daily information—such as how you're feeling, your heart rate, and oxygen levels—using a smartphone app or pulse oximeter. The study will track how often you have COPD flare-ups, whether you go to the hospital, and how your quality of life changes over time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States